Clinical Trials on Solid Tumors and Lymphomas

Total 24209 results

AVEO Pharmaceuticals, Inc.

Terminated

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

Solid Tumors

United States, Canada, Netherlands, India, Russian Federation, Ukraine
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

Solid Tumors

United States
University Health Network, Toronto

Completed

Feasibility Clinical Study of Targeted and Genome-Wide Sequencing

Solid Tumors

Canada
Daiichi Sankyo, Inc.
Medpace, Inc.

Completed

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Solid Tumors

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Solid Tumors

United States
Sanofi

Completed

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Solid Tumors

Belgium, Italy, United States, Spain
Efranat Ltd.

Completed

Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors

Solid Tumors

Israel
M.D. Anderson Cancer Center

Completed

Trial of PBI-05204 in Advanced Cancer Patients

Solid Tumors

United States
Herbert Hurwitz, MD
Novartis; Genentech, Inc.; Amgen

Completed

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) (BEP)

Solid Tumors

United States
Herbert Hurwitz
Genentech, Inc.; Abbott

Completed

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

Solid Tumors

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of LY2523355 in Patients With Solid Cancer (2523355-001)

Solid Tumors

Japan
Pfizer

Completed

Rollover Protocol for Prior SU011248 Protocols

Solid Tumors

United States, Australia, Italy, Greece, Sweden, Switzerland, United Kingdom, Canada, Singapore, France, Netherlands
Novartis Pharmaceuticals

Terminated

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

Solid Tumors

United States
Abbott
Genentech, Inc.

Withdrawn

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Solid Tumors
InnoPharmax Inc.

Completed

Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

Advanced Solid Malignancies | Malignant Lymphomas

Taiwan
Aadi Bioscience, Inc.

Recruiting

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Advanced Solid Tumor | Tumor | Tumor, Solid

United States
Impact Therapeutics, Inc.

Recruiting

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

China, Taiwan, United States, Australia
Partner Therapeutics, Inc.

Withdrawn

Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors (SALIENT)

Solid Tumor | Solid Tumor, Adult

United States
GlaxoSmithKline

Completed

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Solid Tumours

Japan
The First People's Hospital of Lianyungang
Hengrui Yuanzheng Bio-Technology Co., Ltd.

Unknown

Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Excluding T Cell Lymphoma

China
Mereo BioPharma
ICON Clinical Research

Completed

A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.

Advanced Solid Tumor | Metastatic Solid Tumor | Solid Tumor, Adult

United States, United Kingdom
Merus N.V.
Incyte Corporation

Recruiting

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Advanced Cancer | Solid Tumor, Adult | B-cell Lymphoma, Adult

United States, Spain, Belgium, Netherlands
M.D. Anderson Cancer Center

Completed

Bevacizumab and Bortezomib in Patients With Advanced Malignancy

Lymphoma | Solid Tumors | Myeloma | Advanced Malignancy

United States
AstraZeneca

Completed

Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

Advanced Solid Metastatic Tumor

United Kingdom
Shenzhen Ionova Life Sciences Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Cancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, Solid

United States
Fox Chase Cancer Center

Completed

3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
BeiGene

Recruiting

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Solid Tumor | Advanced Solid Tumor | Metastatic Solid Tumor

United States, France, Australia
Quanta Therapeutics

Recruiting

QTX3034 in Patients With KRAS G12D Mutation

Solid Tumors

United States
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

Solid Tumors

Spain, Belgium
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Solid Tumors

Poland, Korea, Republic of, United States, Argentina, Australia, Canada, Colombia, France, Germany, Guatemala, Israel, Italy, Japan, Latvia, Mexico, Peru, Puerto Rico, Romania, South Africa, Spain, Sweden, Turkey, Ukraine
University Health Network, Toronto
Boehringer Ingelheim

Completed

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Solid Tumors

Canada
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

Solid Tumors

United States, Australia, Spain, Germany, France, Switzerland, Netherlands, Canada, Belgium, Italy
Incyte Biosciences Japan GK

Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

Solid Tumors

Japan
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China

Solid Tumors

China
Caris Science, Inc.

Terminated

Caris Molecular Intelligence Registry (CMIR)

Solid Tumors
AstraZeneca
Quintiles, Inc.

Completed

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Solid Tumors

United States, France, United Kingdom, Netherlands
Eli Lilly and Company

Completed

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Solid Tumors

United States
Herbert Hurwitz, MD
GlaxoSmithKline; National Comprehensive Cancer Network; Threshold Pharmaceuticals

Completed

Dose Escalation Study of Pazopanib Plus TH-302 (PATH)

Solid Tumors

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

Solid Tumors

United States
Washington University School of Medicine
Pfizer

Completed

Erlotinib and Temsirolimus for Solid Tumors

Solid Tumors

United States
Quintessence Biosciences, Inc.

Unknown

A Study of QBI-139 in Subjects With Advanced Solid Tumors

Solid Tumors

United States
Emory University
Pfizer; Millennium Pharmaceuticals, Inc.

Completed

A Phase I Trial of Bortezomib and Sunitinib

Solid Tumors

United States
Daiichi Sankyo, Inc.

Completed

Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

Solid Tumors

United States
National University Hospital, Singapore

Unknown

Characterisation of Gene Variants in the Angiogenic Pathway

Solid Tumors

Singapore
University of Chicago
Pfizer

Completed

Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers

Solid Tumors

United States
National University Hospital, Singapore

Completed

Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle

Solid Tumors

Singapore
Millennium Pharmaceuticals, Inc.

Completed

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Solid Tumors

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Solid Tumor | Tumor | Malignant Lymphoma

United States
Chinese PLA General Hospital

Recruiting

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Advanced Solid Tumors | Relapsed/Refractory Non-Hodgkin Lymphoma

China
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary

3

Subscribe